UCB - Sales Revenues

Stock Price
264.50
Daily Change
-3.30 -1.23%
Monthly
4.59%
Yearly
64.44%
Q2 Forecast
245.65

UCB reported EUR4.25B in Sales Revenues for its fiscal semester ending in December of 2025.





Sales Change Date
Alcon AG USD 2.7B 110M Dec/2025
Almirall EUR 547.63M 12.83M Dec/2025
Amarin USD 49.22M 451K Dec/2025
argenx SE USD 1.12B 132.91M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bayer EUR 11.44B 1.78B Dec/2025
Galapagos EUR 900.82M 835.52M Dec/2025
Genmab DKK 1.06B 36M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
GRIFOLS EUR 1.98B 110M Dec/2025
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.25B 70M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Orion EUR 695.3M 272.1M Dec/2025
Recordati EUR 662M 37.65M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
UCB EUR 4.25B 764M Dec/2025
Unibail Rodamco EUR 1.49B 77M Dec/2025